MitsubishiTanabe Pharma

November 11, 2019		Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)
November 11, 2019		HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019
November 11, 2019		Mitsubishi Tanabe Pharma Corporate Report 2019
November 1, 2019		IR Meeting for FY2019 2nd Quarter Business Results[Transcript]
October 31, 2019		IR Meeting for FY2019 2nd Quarter Business Results[Audio]
October 30, 2019		Announcement of FY2019 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 30, 2019		IR Meeting for FY2019 2nd Quarter Business Results[Material]
October 25, 2019		Revision to the First Half Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020
October 25, 2019		Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019
October 11, 2019		Corporate Governance Corporate Governance Report
October 9, 2019		Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions
October 2, 2019		Opinion Sharing Meeting on ESG [Transcript]
October 2, 2019		Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines（MT-2271）by Health Canada
October 1, 2019		CSR Information updated
September 30, 2019		Opinion Sharing Meeting on ESG [Video]
September 30, 2019		Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ～Targeting treatments for infectious diseases that burden the developing countries～
September 27, 2019		Opinion Sharing Meeting on ESG [Material]
September 24, 2019		NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China
September 20, 2019		Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion Ophthalmic Solution 0.05% and Alesion LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.
September 18, 2019		Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
September 17, 2019		Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil
September 4, 2019		Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product
August 30, 2019		Monitoring indicators on “Materiality”
August 28, 2019		The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease
August 8, 2019		PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US IND
August 8, 2019		Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)
August 7, 2019		NMPA approved Japan-originated ALS treatment Edaravone in China
August 6, 2019		Commencement of R&D of Gene Therapy Product for Hemophilia B
July 31, 2019		IR Meeting for FY2019 1st Quarter Business Results[Transcript]
July 29, 2019		IR Meeting for FY2019 1st Quarter Business Results[Material][Audio]
July 29, 2019		Announcement of FY2019 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 23, 2019		Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemia
June 24, 2019		Corporate Governance Report
June 21, 2019		Notice of Resolution of the 12th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 24, 2019)
May 30, 2019		Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union
May 29, 2019		Launch of SIMPONI Subcutaneous Injection 50mg Autoinjector
May 24, 2019		Notice of Convocation of the 12th Ordinary General Meeting of Shareholders
May 16, 2019		IR Meeting for FY2018 Business Results[Transcript]
May 13, 2019		IR Meeting for FY2018 Business Results[Material][Video]
May 10, 2019		Announcement of Financial Results for FY2018 ⇒R&D Pipeline "State of New Product Development"
May 7, 2019		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018[Transcript]
April 26, 2019		Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases
April 26, 2019		Medicago announced that its proprietary plant-based production platform, Proficia was awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress in Washington, D.C.
April 24, 2019		Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018 [Material][Audio]
April 24, 2019		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
April 15, 2019		For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in China
April 11, 2019		Notice Regarding Reorganization of Research, Production, and Technology Bases
March 28, 2019		The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution
March 26, 2019		AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
March 20, 2019		Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative Office
March 12, 2019		Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD
February 28, 2019		Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in China
February 20, 2019		Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration
February 14, 2019		FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
February 12, 2019		First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App
February 7, 2019		IR Meeting for FY2018 3rd Quarter Business Results[Transcript]
February 6, 2019		Swissmedic approves RADICAVA, Japan-originated ALS treatment
February 4, 2019		IR Meeting for FY2018 3rd Quarter Business Results[Material][Audio]
February 4, 2019		Announcement of FY2018 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 4, 2019		Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.
December 11, 2018		HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
December 10, 2018		Conduct a study to identify and measure specific biomarkers in ALS - we will strive to deliver a beneficial therapy option to patients -
November 21, 2018		Business Briefing [Video]
November 20, 2018		"Materiality" posted
November 19, 2018		Notice Regarding Revision of Medium-Term Management Plan 16-20: Open Up the Future
November 19, 2018		Business Briefing [Material]
November 15, 2018		Mitsubishi Tanabe Pharma to present New data on Investigational Oral Suspension of Edaravone for ALS at 29th International Symposium on ALS/MND
October 30, 2018		IR Meeting for FY2018 2nd Quarter Business Results[Material][Audio]
October 30, 2018		Announcement of FY2018 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 22, 2018		Strategic Research Collaboration for the Development of Innovative Antibody Drug to Treat Autoimmune Diseases
October 9, 2018		Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
October 5, 2018		For the ALS patients in Canada, we hope to deliver Japan-originated ALS treatment ―Health Canada approves RADICAVA (edaravone) for the treatment of ALS
September 26, 2018		Company name changes of our oversea subsidiaries
September 26, 2018		Mitsubishi Tanabe Pharma Corporate Report 2018
September 18, 2018		Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
July 30, 2018		IR Meeting for FY2018 1st Quarter Business Results[Material][Audio]
July 30, 2018		Announcement of FY2018 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 27, 2018		Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria
July 19, 2018		Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―
July 2, 2018		Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -
July 2, 2018		Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -
June 28, 2018		Mitsubishi Tanabe Pharma and Janssen Pharmaceutical　K.K. update co-promotion framework for STELARA, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA to treat adults with Crohn’s disease in Japan
June 25, 2018		Corporate Governance Report
June 22, 2018		Notice of Resolution of the 11th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 25, 2018)
June 14, 2018		TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan
May 30, 2018		Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companies
May 28, 2018		For the ALS patients in the world,we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALS
May 25, 2018		Notice of Convocation of the 11th Ordinary General Meeting of Shareholders
May 18, 2018		Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize fromthe Japan Chemical Industry Association (JCIA)
May 10, 2018		IR Meeting for FY2017 Business Results[Material][Video]
May 9, 2018		Announcement of Financial Results for FY2017 ⇒R&D Pipeline "State of New Product Development"
April 10, 2018		Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life Science
April 10, 2018		To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in Canada
March 26, 2018		Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
March 6, 2018		Name Change of our Singapore Subsidiary
March 1, 2018		Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in Taiwan
February 28, 2018		Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrup
February 5, 2018		IR Meeting for FY2017 3rd Quarter Business Results[Material][Audio]
February 5, 2018		Announcement of FY2017 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 23, 2018		Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
January 16, 2018		Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical Market
January 11, 2018		Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―
December 20, 2017		Update of Previous Disclosure ― License Agreement with Kolon Life Science on Invossa
December 13, 2017		Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS
December 5, 2017		Business Briefing [Material][Video]
December 1, 2017		CSR Information updated
November 22, 2017		Launch of Rupafin tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
November 8, 2017		Distribution Agreement for Clenafin/Jublia in Taiwan
November 1, 2017		IR Meeting for FY2017 2nd Quarter Business Results[Material][Audio]
November 1, 2017		Announcement of FY2017 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
November 1, 2017		Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S.
November 1, 2017		Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia
October 24, 2017		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2018
October 18, 2017		Completion of Acquisition of NeuroDerm (100% Ownership)
October 11, 2017		Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by the companies-
October 2, 2017		Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure)
September 29, 2017		Organizational Change and Personnel Change
September 27, 2017		Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
September 27, 2017		Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza Vaccine
September 27, 2017		R&D Meeting [Material]
September 22, 2017		Mitsubishi Tanabe Pharma Corporate Report 2017
September 13, 2017		Approval of Mitsubishi Tanabe Pharma’s Acquisition of NeuroDerm at NeuroDerm’s General Meeting of Shareholders
September 7, 2017		Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent-Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-
September 4, 2017		Start of Operations of Vaccine Manufacturing Joint Venture: BIKEN Co., Ltd.
August 17, 2017		Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
August 9, 2017		RADICAVA to treat ALS now available in U.S.
July 31, 2017		IR Meeting for FY2017 1st Quarter Business Results[Material][Audio]
July 31, 2017		Announcement of FY2017 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 27, 2017		Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199
July 24, 2017		Analysts meeting on acquisition of NeuroDerm [Material][Audio]
July 24, 2017		Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.
July 3, 2017		Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-
June 30, 2017		Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products Business
June 22, 2017		Corporate Governance Report
June 21, 2017		Notice of Resolution of the 10th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 22, 2017)
June 20, 2017		Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court
June 1, 2017		Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―
May 23, 2017		Notice of Convocation of the 10th Ordinary General Meeting of Shareholders
May 18, 2017		Approval for partial change in administration / dosage for Crohn’s disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
May 16, 2017		Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS
May 11, 2017		IR Meeting for FY2016 Business Results[Material][Video]
May 10, 2017		Differences Between Non-Consolidated Actual Results for FY2015 and FY2016
May 10, 2017		Announcement of Financial Results for FY2016 ⇒R&D Pipeline "State of New Product Development"
May 10, 2017		Notice of Dividend of Retained Earnings
May 10, 2017		Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin Preparation
May 9, 2017		Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.
May 8, 2017		New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA (edaravone) for the treatment of ALS
April 26, 2017		Introduction of Performance-Linked Stock Compensation Plan for Board Directors
April 24, 2017		Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus
April 17, 2017		Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region
March 30, 2017		Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF α
March 29, 2017		Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA Tablets, a selective DPP-4 inhibitor, and CANAGLU Tablets, an SGLT2 inhibitor
March 28, 2017		Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of Subsidiary
February 6, 2017		Announcement of FY2016 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 6, 2017		IR Meeting for FY2016 3rd Quarter Business Results[Material][Audio]
February 3, 2017		Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s disease
January 27, 2017		Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303
December 9, 2016		12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND
December 7, 2016		Business Briefing [Material][Video]
November 7, 2016		Basic Agreement on the Establishment of a Joint Venture
November 1, 2016		Announcement of FY2016 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
November 1, 2016		IR Meeting for FY2016 2nd Quarter Business Results[Material][Audio]
November 1, 2016		Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritis
October 25, 2016		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017
October 5, 2016		CSR Activities Report 2016
October 5, 2016		Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―
October 4, 2016		Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine Tablets
September 6, 2016		Application for partial change in administration/dosage for Crohn's disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
August 30, 2016		FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
August 30, 2016		Mitsubishi Tanabe Pharma Corporate Report 2016
August 26, 2016		Valixa Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients
August 23, 2016		Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets -
August 2, 2016		Announcement of FY2016 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
August 2, 2016		IR Meeting for FY2016 1st Quarter Business Results[Material][Audio]
June 23, 2016		Corporate Governance Report
June 22, 2016		Regarding Nomination Committee and Compensation Committee
June 22, 2016		Notice of Resolution of the 9th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 23, 2016)
June 20, 2016		Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
June 6, 2016		Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund
May 20, 2016		Notice of Convocation of the 9th Ordinary General Meeting of Shareholders
May 13, 2016		Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in Psoriasis
May 13, 2016		Corrections with respect to “Summary of Financial Results for year ended March 31, 2016”　(Japan GAAP) (Consolidated)
May 12, 2016		IR Meeting for FY2015 Business Results[Material][Audio]
May 11, 2016		Announcement of Financial Results for FY2015 ⇒R&D Pipeline "State of New Product Development"
May 11, 2016		Notice of Dividend of Retained Earnings
April 27, 2016		Change of Representative Director, Director and Corporate Auditor
April 20, 2016		Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting
April 4, 2016		MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore
March 29, 2016		Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
March 22, 2016		Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
March 15, 2016		Corporate Governance Report
March 10, 2016		Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)
February 23, 2016		Mitsubishi Tanabe Pharma Enhances Operations in the United States
February 3, 2016		Announcement of FY2015 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 3, 2016		IR Meeting for FY2015 3rd Quarter Business Results[Material][Audio] ⇒[Q&A](February 9, 2016)
February 3, 2016		Notice Regarding Results of Early Retirement Program
December 21, 2015		Remicade for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment
December 21, 2015		RADICUT inj. 30mg and RADICUT Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea
December 15, 2015		Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
December 7, 2015		Corporate Governance
December 1, 2015		IR Meeting for Medium-Term Management Plan [Material][Audio] ⇒[Q&A](December 17, 2015)
November 30, 2015		Formulation of the Medium-Term Management Plan 16-20: Open Up the Future
November 20, 2015		Announcement of an approval for an additional indication for the Anti-depressant, Lexapro Tablets 10 mg in Japan
November 19, 2015		CSR Activities Report 2015
October 30, 2015		Announcement of FY2015 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 30, 2015		IR Meeting for FY2015 2nd Quarter Business Results[Material][Audio] ⇒[Q&A](November 10, 2015)
October 30, 2015		Notice Regarding Implementation of Early Retirement Program
October 30, 2015		Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies
October 2, 2015		Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody
September 30, 2015		Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016
September 23, 2015		MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
September 18, 2015		Mitsubishi Tanabe Pharma Corporate Report 2015
September 17, 2015		Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia
September 15, 2015		MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan
September 9, 2015		Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases
August 24, 2015		Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for Additional Indications for Entero-Behcet's Disease, Neuro-Behcet's Disease, and Vasculo-Behcet's Disease
July 31, 2015		Announcement of FY2015 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 31, 2015		IR Meeting for FY2015 1st Quarter Business Results[Material][Audio] ⇒[Q&A](August 6, 2015)
July 27, 2015		Organizational Restructuring
July 10, 2015		Application Filed for a Partial Change in Dosage and Usage of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, in Psoriasis
June 26, 2015		RADICUT inj. 30mg and RADICUT BAG for I.V. Infusion 30mg Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan
June 19, 2015		Notice of Resolution of the 8th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 22, 2015)
June 3, 2015		Partial Correction to Notice of Resolution of the 8th Ordinary General Meeting of Shareholders
May 26, 2015		Approval for Additional Pediatric Indications in Japan Received for TALION Tablets and TALION OD Tablets, Anti-Allergic Agents
May 22, 2015		Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund
May 21, 2015		Notice of Convocation of the 8th Ordinary General Meeting of Shareholders
May 11, 2015		IR Meeting for FY2014 Business Results[Material][Audio] ⇒[Q&A](May 18, 2015)
May 8, 2015		Announcement of Financial Results for FY2014 ⇒R&D Pipeline "State of New Product Development"
May 8, 2015		Notice of Dividend of Retained Earnings
April 1, 2015		Execution of License Agreement on VMAT2 Inhibitor NBI-98854
February 25, 2015		Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government
February 25, 2015		Reorganization of research bases in Japan
February 6, 2015		Completion of Construction of the New Head Office Building
February 2, 2015		Conference Call for FY2014 3rd Quarter Business Results [Material] [Audio] ⇒[Q&A](February 6, 2015)
February 2, 2015		Announcement of FY2014 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 29, 2015		-Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets -Completion of New Manufacturing FacilityTianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia
December 18, 2014		Reorganization of the U.S. Affiliates to Accelerate the U.S. Operations Expansion
November 28, 2014		Notice regarding conclusion of the final agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.
November 13, 2014		Application filed for additional indication for ALS for RADICUT inj. 30mg and RADICUT BAG for I.V. Infusion 30mg
November 6, 2014		Supporting “good blood glucose control” in Japanese patients with diabetes joint promotion with Johnson & Johnson K.K. Medical Company
October 30, 2014		Applications filed for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for additional indications for entero-Behcet’s disease, neuro-Behcet’s disease, and vasculo-Behcet’s disease
October 30, 2014		IR Meeting for FY2014 2nd Quarter Business Results[Material] [Audio] ⇒[Q&A](November 7, 2014)
October 29, 2014		Announcement of FY2014 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 23, 2014		CSR Activities Report 2014
October 21, 2014		Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2015
September 19, 2014		TELAVIC 250mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2
September 5, 2014		Mitsubishi Tanabe Pharma Corporate Report 2014
September 2, 2014		Launch of CANAGLU Tablets 100mg A SGLT2 inhibitor for Type2 Diabetes Mellitus
August 20, 2014		MITSUBISHI TANABE PHARMA CORPORATION AND ASTRAZENECA ANNOUNCE RESEARCH COLLABORATION IN DIABETIC NEPHROPATHY
July 29, 2014		IR Meeting for FY2014 1st Quarter Business Results[Material] [Audio] ⇒[Q&A](August 5, 2014)
July 29, 2014		Announcement of FY2014 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 4, 2014		Marketing and Manufacturing Approval in Japan Received for CANAGLU Tablets 100mg
June 30, 2014		Notice regarding conclusion of a basic agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.
June 30, 2014		Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS)
June 20, 2014		Notice of Resolution of the 7th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 23, 2014)
June 16, 2014		Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes Association
May 30, 2014		Name Change of Group Company in China
May 29, 2014		Announcement of Merger (Simplified Merger and Short form Merger) of Consolidated Subsidiary
May 29, 2014		Notice of Convocation of the 7th Ordinary General Meeting of Shareholders
May 28, 2014		Name Change of Consolidated Subsidiaries in Europe
May 9, 2014		IR Meeting for FY2013 Business Results[Material] [Audio] ⇒[Q&A](May 19, 2014)
May 8, 2014		Announcement of Financial Results for FY2013 ⇒R&D Pipeline "State of New Product Development"
April 23, 2014		Change of Representative Directors and Personnel
April 22, 2014		R&D "Clinical Trial Information"
February 6, 2014		Change of Representative Directors
February 3, 2014		Conference Call for FY2013 3rd Quarter Business Results [Material] [Audio] ⇒[Q&A](February 10, 2014)
February 3, 2014		Announcement of FY2013 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 3, 2014		MT-4666 in Alzheimer’s Disease Start of Global Phase 3 Clinical Trial Program, COGNITIV AD
January 16, 2014		TELAVIC 250mg Tablets, Antiviral Application for additional Indication for Chronic Hepatitis C Genotype 2
December 20, 2013		TENELIA 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy
November 1, 2013		IR Meeting for FY2013 2nd Quarter Business Results[Material] [Audio] ⇒[Q&A](November 8, 2013)
October 30, 2013		Announcement of FY2013 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 21, 2013		CSR Report 2013
September 30, 2013		Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law of Japan
September 25, 2013		Revision to 2Q Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2014
September 19, 2013		Mitsubishi Tanabe Pharma to Open Singapore Office
September 19, 2013		Notice Regarding Completion of Acquisition of Shares of Medicago, Inc., a Pharmaceutical Company Based in Canada, Which Has Become a Subsidiary of Mitsubishi Tanabe Pharma
September 9, 2013		Tanabe Indonesia to Construct New Production Facility in Indonesia
August 8, 2013		Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc.
August 6, 2013		Annual Report 2013
August 6, 2013		Tianjin Tanabe Seiyaku to Construct New Production Facility in China
August 1, 2013		Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.'s domestic production sites and the conclusion of a basic agreement regarding the transfer of its Ashikaga Plant
July 31, 2013		Conference Call for FY2013 1st Quarter Business Results [Material] [Audio] ⇒[Q&A](August 7, 2013)
July 31, 2013		Announcement of FY2013 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 12, 2013		Notice regarding the acquisition of Medicago Inc.
June 27, 2013		VIVUS gains MAA approval for TA-1790 in the EU
June 21, 2013		Notice of Resolution of the 6th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 24, 2013)
June 14, 2013		Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE Tablets: Selective β1 Blocker
May 30, 2013		Notice of Convocation of the 6th Ordinary General Meeting of Shareholders
May 27, 2013		New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes
May 9, 2013		IR Meeting for FY2012 Business Results[Material] [Audio] ⇒[Q&A](May 20, 2013)
May 8, 2013		Announcement of Financial Results for FY2012 ⇒R&D Pipeline "State of New Product Development"
April 30, 2013		Change of Directors
April 3, 2013		Launch of BindRen for Treatment of Hyperphosphatemia in Germany and Austria
April 1, 2013		Transfer of Tanabe Europe’s shares
April 1, 2013		U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
February 28, 2013		Approval for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
February 26, 2013		TENELIA 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy
February 21, 2013		Information Meeting [Material][Audio] ⇒[Q&A](March 1, 2013)
February 21, 2013		Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
February 1, 2013		Conference Call for FY2012 3rd Quarter Business Results [Material][Audio] ⇒[Q&A](February 8, 2013)
February 1, 2013		Announcement of FY2012 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 29, 2013		BindRen Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia
October 29, 2012		Conference Call for FY2012 2nd Quarter Business Results [Material][Audio] ⇒[Q&A](November 5, 2012)
October 29, 2012		Announcement of FY2012 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 26, 2012		Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine
October 19, 2012		Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
October 11, 2012		CSR Report 2012
October 10, 2012		Outcome of Global Phase III (EPPIC) Studies
October 1, 2012		Outsourcing of Logistics Operations
September 28, 2012		Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
September 20, 2012		Launch of "Simponi”, a human TNFα monoclonal antibody in Indonesia
September 13, 2012		MAINTATE Tablets: Selective β1 Antagonist Notice regarding application for additional indication for chronic atrial fibrillation
August 31, 2012		Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
August 31, 2012		Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation
August 28, 2012		Launch of TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
August 21, 2012		Annual Report 2012
July 31, 2012		Conference Call for FY2012 1st Quarter Business Results [Material][Audio] ⇒[Q&A](July 31, 2012)
July 31, 2012		Announcement of FY2012 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 23, 2012		Launch of Tranquilizer, DEPAS TABLETS 0.25 mg
July 6, 2012		Launch of Argatroban, a Selective Antithrombin Agent, in UK
June 29, 2012		Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
June 22, 2012		Notice of Resolution of the 5th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 25, 2012)
June 22, 2012		IR "Financial Data"
June 6, 2012		Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
June 1, 2012		Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
May 15, 2012		Notice Regarding Transfer of Fine Chemical Operations
May 14, 2012		R&D "Clinical Trial Information"
May 10, 2012		IR Meeting for FY2011 Business Results[Material] [Audio] ⇒[Q&A](May 18, 2012)
May 9, 2012		Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia
May 8, 2012		Announcement of Financial Results for FY2011 ⇒R&D Pipeline "State of New Product Development"
May 8, 2012		Notice of Dividend of Retained Earnings
May 8, 2012		New Organization in Plasma Fractionation Operations Establishment of “Japan Blood Products Organization”
May 8, 2012		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody A New Option to Shorten Infusion Time
May 8, 2012		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody Lifting of Condition on Approval for Psoriasis
May 7, 2012		VIVUS gains NDA approval for TA-1790 in the US
March 29, 2012		Launch of "SIMPONI”, a human TNFα monoclonal antibody in Taiwan
March 21, 2012		“IMUSERA Capsules 0.5mg” Multiple Sclerosis Treatment AgentNotice regarding revision of “warnings” and “important basic precautions” sections of prescribing information
March 7, 2012		Conclusion of Research Collaboration Agreement for Next-Generation Vaccines
March 6, 2012		Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan Companies conclude joint sales agreement for two treatments for type 2 diabetes mellitus - MP-513 and TA-7284
January 31, 2012		Conference Call for FY2011 3rd Quarter Business Results [Material][Audio] ⇒[Q&A](February 6, 2012)
January 31, 2012		Announcement of FY2011 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 16, 2012		Conclusion of Licensing Agreement for Hib Vaccine
December 1, 2011		Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN
November 25, 2011		Launch of "IMUSERA Capsules 0.5mg"Japan's First Oral Dosing Multiple Sclerosis Treatment with Novel Mode of Action
November 25, 2011		Launch of Antiviral Agent "TELAVIC Tablets 250 mg"Novel Mode of Action for Chronic Hepatitis C Treatment
November 25, 2011		Approval of Additional Indication for MODIODAL Tablets 100 mg a Sleep Disorder Treatment
November 21, 2011		CSR Report 2011
November 18, 2011		Notice of postponement of integrating the plasma fractionation operations of the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation
October 31, 2011		Conference Call for FY2011 2nd Quarter Business Results [Material][Audio] [Q&A](November 7, 2011)
October 31, 2011		Announcement of FY2011 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
October 31, 2011		Revision of Dividend of Retained Earnings and Year-end Dividend Forecast
October 21, 2011		Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820
October 19, 2011		IR Meeting for Medium-Term Management Plan[Material][Audio] [Q&A](October 28, 2011)
October 17, 2011		Formulation of Medium-Term Management Plan 11-15 New Value Creation ＜Presentation Material＞
September 26, 2011		Approval for "IMUSERA Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment
September 26, 2011		Approval for TELAVIC 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment
September 26, 2011		Approval for Additional Indication of Generalized Myasthenia GravisVenoglobulinIH 5% for Intravenous Injection,a Human Immunoglobulin Preparation Derived from Donated Plasma
September 22, 2011		Presentation Material for Deutsche Securities Japan Pharmaceutical Conference 2011
September 15, 2011		Launch of "SIMPONI (golimumab) Subcutaneous Injection 50mg Syringe" A Treatment of Rheumatoid Arthritis
September 1, 2011		New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment
August 31, 2011		Annual Report 2011
August 31, 2011		R&D "Clinical Trial Information"
August 22, 2011		Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent Litigation
August 17, 2011		Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn’s Disease
August 17, 2011		R&D "Clinical Trial Information"
August 4, 2011		Conference Call for FY2011 1st Quarter Business Results [Q&A〕
July 29, 2011		Conference Call for FY2011 1st Quarter Business Results [Material〕[Audio]
July 29, 2011		Announcement of FY2011 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 29, 2011		Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012
July 21, 2011		The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro 10mg
July 19, 2011		Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma Corporation
July 1, 2011		Approval for "SIMPONI Subcutaneous Injection 50mg Syringe(Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis
June 22, 2011		Notice of Resolution of the 4th Ordinary General Meeting of Shareholders
June 17, 2011		Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operations
June 2, 2011		AZANIN Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases
May 27, 2011		Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia
May 20, 2011		Approval for Additional Indication for selective β1 antagonist, MAINTATE Tablets 0.625, 2.5, and 5 and Launch of MAINTATE Tablets 0.625
May 20, 2011		Approval for Additional Indications for the Selective Antithrombin Agents,Novastan HI Injection 10 mg/2mL and Slonnon HI Injection 10 mg/2mL
May 20, 2011		Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)
May 19, 2011		IR Meeting for FY2010 Business Results [Q&A〕
May 12, 2011		IR Meeting for FY2010 Business Results[Material] [Audio]
May 10, 2011		Announcement of Financial Results for FY2010 ⇒R&D Pipeline "State of New Product Development"
May 10, 2011		Partial Amendment of the Articles of Incorporation
April 27, 2011		Change of Directors, and Organization
April 27, 2011		Summary of the Quality Control Incident
April 11, 2011		Impact of the Great East Japan Earthquake (3rd Notice)
March 30, 2011		Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice)
March 28, 2011		Novartis receives European Commission approval for FTY720, the first oral multiple sclerosis treatment for use in the EU
March 15, 2011		Impact of the 2011 off the Pacific coast of Tohoku Earthquake
March 14, 2011		Mitsubishi Tanabe Pharma Supports Japan Earthquake Relief Efforts ⇒Mitsubishi Chemical Holdings Group：Aid for Areas Affected
March 11, 2011		Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and clinical research project for CKD drugs-
March 7, 2011		Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai
January 28, 2011		Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment
January 28, 2011		Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market
January 26, 2011		Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)
January 11, 2011		"Kremezin", Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan
December 21, 2010		Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea
December 20, 2010		Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment
December 14, 2010		Commencement of R&D Partnership with Anaphore for Atrimer Technology (Novel Trivalent Proteins)
December 9, 2010		R&D Meeting [Q&A]
December 1, 2010		Removal of Grace Period
December 1, 2010		R&D Meeting[Material] [Audio]
October 29, 2010		Notice Regarding Change in the Number of Shares Constituting One Trading Unit and Partial Amendments to the Articles of Incorporation
September 28, 2010		Novartis gains NDA approval for FTY720 in the US
June 16, 2010		Notice Regarding Submission of Business Improvement Plans
April 13, 2010		Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law
January 7, 2010		Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan
December 21, 2009		Name Change of Pharmaceutical Manufacturing & Sales Subsidiaryin Korea (Welfide Korea Co., Ltd.)
October 13, 2009		Establishment of Pharmaceutical Sales & Marketing Company and Reorganization of Group Companies in the U.S.
April 10, 2009		Standard for our company’s payment burdens related to fees required for benefit payments and other operations, based on “the Special Relief Law Concerning the Payment of Benefits to Relieve the Patients of Hepatitis C (abbreviated title)”
March 24, 2009		Withdrawal of Marketing Authorization for Recombinant Human Serum Albumin Preparation “Medway Injection 5%” and Voluntary Recall of “Medway Injection 5%” and “Medway Injection 25%”
September 19, 2008		The Basic Agreement to Be Concluded with the National Plaintiffs Group on the HCV Class Action
May 7, 2008		Announcement of Corporate Behavior Charter and Medium-Term Management Plan
October 1, 2007		Announcement of the Establishment of Mitsubishi Tanabe Pharma Corporation